Kestra Medical Technologies officer Traci Umberger sells $512,791

KIRKLAND, WA – Traci S. Umberger, General Counsel and Chief Administrative Officer and a Director at Kestra Medical Technologies, Ltd. [KMTS], recently sold common shares totaling $512,791. The sales, which occurred between July 30 and August 3, 2026, involved weighted average prices ranging from $22.6048 to $23.8553.

These transactions were nondiscretionary, executed to satisfy tax withholding obligations linked to the vesting and settlement of restricted stock units.The sales come as KMTS shares have surged 75% over the past year, currently trading at $28.02, near the stock’s 52-week high of $30.00. According to InvestingPro analysis, the stock appears overvalued relative to its Fair Value estimate, placing it among companies on the most overvalued list. The medical technology company currently carries a market capitalization of $1.63 billion.

On July 30, 2026, Ms. Umberger disposed of 5,887 common shares at a weighted average price of $22.7437 per share. The prices for these specific shares ranged from $22.2400 to $23.1700.

The following day, July 31, 2026, an additional 8,752 common shares were sold at a weighted average price of $22.6048. The individual share prices for this transaction varied between $22.1700 and $22.9200.

The final reported sale took place on August 3, 2026, involving 7,590 common shares. These shares were sold at a weighted average price of $23.8553, with prices ranging from $23.6500 to $24.2800.

Following these reported transactions, Ms. Umberger directly beneficially owns 199,405 common shares.

In other recent news, Kestra Medical Technologies reported a significant increase in revenue for its fiscal fourth quarter of 2026, with sales climbing 66% year-over-year to $28.64 million. Despite this revenue growth, the company posted an adjusted earnings per share loss of $0.67, missing the forecasted loss of $0.58. Stifel reiterated a Buy rating on Kestra Medical, maintaining a price target of $30.00, due to strong growth and record prescriptions for its ASSURE wearable cardioverter-defibrillator. Wolfe Research also raised its price target to $30.00, citing better-than-expected execution by the company. JPMorgan initiated coverage with an Overweight rating, highlighting the potential of Kestra’s ASSURE device in a market dominated by a single incumbent for over two decades. Oppenheimer started coverage with a Perform rating, noting Kestra’s increasing market share and the substantial total addressable market. These recent developments reflect Kestra Medical’s ongoing efforts to expand its presence in the wearable medical device market.